Valeric acid from oral microbiome suppresses esophageal cancer growth by disrupting eEF1A1 -mediated translational output

Read full text Summarise with VIRAT
Authors: Yuanpeng He, Hao Peng, Lianglan Li, Siqi Sheng, Qi Wang, Weiqin Li, Fengqing Lin, Jun Yi
Cited by: 0
References: 69

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Dysbiosis of the oral microbiome has been associated with esophageal squamous cell carcinoma (ESCC), but how it impacts ESCC remains largely unknown. Surprisingly, we find that the oral microbiota derived from ESCC patients—not that from healthy controls—exhibits potent inhibitory and cytotoxic effects on ESCC cells. This anti-tumor effect is attributable to Veillonella, which is enriched in the ESCC-associated microbiota. Mechanistically, Veillonella produces valeric acid, which is transported into cells via MCT1 and inhibits the GTPase activity of eEF1A1, thereby suppressing protein translation. These findings identify valeric acid as a potential postbiotic for ESCC treatment and underscore the necessity of functional validation beyond observational and correlative studies. A link between the oral microbiome and oesophageal squamous cell carcinoma (ESCC) has previously been reported but whether it has a causal role is unclear. Here, the authors identify oral Veillonella-derived valeric acid as having a tumour suppressive function in ESCC via interaction with the elongation translational factor, eEF1A1.

Fields of Study & Subjects

Oral microbiology and periodontitis research Gut microbiota and health Bacterial Cancer Therapy

Publication details

Journal / source
Nature Communications
Volume
17
Issue
1
Publication date
27 March 2026
Language
EN